Our gratitude goes out to the individuals, families, and healthcare providers who participated in the clinical trial that led to the approval of TECENTRIQ for PD-L1+ metastatic triple-negative breast cancer (mTNBC). Thank you for your courage in the fight against cancer.

Tips for talking to your doctor about TECENTRIQ

Talk to your Doctor about TECENTRIQ (atezolizumab) for mTNBC

Support and information

TECENTRIQ (atezolizumab) Support and Information

Financial assistance options

TECENTRIQ (atezolizumab) Financial Support